This medication has REMS requirements. REMS, or Risk Evaluation and Mitigation Strategy, requirements are put in place to ensure the safe use of certain medications with known risks. The requirements aim to minimize the potential risks while allowing patients to access prescribed medications. For more information about the REMS requirements for patient and prescriber enrollment and to access the enrollment forms, please visit the manufacturer website here.
Please print and complete the forms below. Once completed, fax to the number indicated on the form.
- Adempas® (riociguat) Therapy Referral Form
- Adempas® (riociguat) REMS Patient Enrollment and Consent Form
Getting your patient started on PAH therapy
Pulmonary arterial hypertension (PAH) is characterized as WHO Group 1. The diagnosis of PAH may require confirmation with a complete right heart catherization. The current hemodynamic definition of PAH is a mean pulmonary artery pressure greater than 25mmHg; a pulmonary capillary wedge pressure, or left ventricular end-diastolic pressure less than or equal to 15mmHg; and a pulmonary vascular resistance greater than 3 Wood units.
Manufacturer link below for additional drug information